ACOG
NASDAQAlpha Cognition Inc.
Alpha Cognition Inc. (ACOG) is a public company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for ACOG, including 2 press releases and news items, 2 insider trades and 1 earnings update. The most recent was published Nov 2, 2026.
Financial highlights
Full financials- Revenue, TTM
- $15.26M
- Net income, TTM
- -$23.44M
- Net margin
- -153.6%
- Free cash flow, TTM
- -$31.18M
- Cash
- $41.38M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks43-43%
2026-05-102026-11-01
Mix1790d
- Other7(41%)
- Insider6(35%)
- Earnings2(12%)
- SEC Filings1(6%)
- Analyst1(6%)
Latest news
25 items- PRAlpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business UpdateAlpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2026 financial results and provide a business update on Wednesday, November 11, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its third quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website. Following the release, management will host a conference call to review financial and operating results. Details for the conference call can be
- INSIDERLarge owner Opaleye Management Inc. bought $265,820 worth of shares (32,090 units at $8.28) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. bought $308,576 worth of shares (36,940 units at $8.35) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- PRAlpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent Application No. 19/090,242, titled "Process for Preparing Benzgalantamine and Salts Thereof," on October 1, 2026, as U.S. Patent Application Publication No. US 2026/0297103 A1. The published patent application covers Alpha Cognition's proprietary manufacturing technology for benzgalantamine, the active ingredient in ZUNVEYL®. The application includes innovations designed to improve manufacturing effi
- PRAlpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall CongressPresentations will highlight data on cognition, function, neuropsychiatric symptoms, sleep, gastrointestinal tolerability, treatment patterns and psychotropic medication utilization in Alzheimer’s disease Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, taking place October 29-November 1, 2026 and Neuroscience Education Institute (NEI) Fall Congress, taking place Novemb
- PRAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 6,000 shares of common stock to a new non-executive employee under the Company’s 2026 Inducement Grant Plan. The 2026 Inducement Grant Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company. The Compensation Committee approved the st
- INSIDERLarge owner Opaleye Management Inc. bought $165,634 worth of shares (19,050 units at $8.69) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- PRAlpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term CareAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalantamine), donepezil, galantamine or rivastigmine. These measures provide insight into how treatment is used in real-world long-term care settings, including whether residents reach therapeutic dosing and how their broader medication regimens change over time. The ana
- INSIDERLarge owner Opaleye Management Inc. bought $270,800 worth of shares (31,763 units at $8.53) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Alpha Cognition Inc.SCHEDULE 13G - Alpha Cognition Inc. (0001655923) (Subject)
- INSIDERLarge owner Opaleye Management Inc. bought $1,062,506 worth of shares (123,918 units at $8.57) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- PRAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on September 8, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 25,000 shares of common stock to a new non-executive employee under the Company’s 2026 Inducement Grant Plan. The 2026 Inducement Grant Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company. The Compensation Committee approved the
- PRAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on August 31st, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 20,000 shares of common stock to a new non-executive employee under the Company’s 2026 Inducement Grant Plan. The 2026 Inducement Grant Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company. The Compensation Committee approved the
- INSIDERDirector Wills Robert James bought $96,200 worth of shares (10,000 units at $9.62), increasing direct ownership by 45% to 32,241 units (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- ANALYSTB. Riley Securities initiated coverage on Alpha Cognition with a new price targetB. Riley Securities initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $21.00
- SECSEC Form 10-Q filed by Alpha Cognition Inc.10-Q - Alpha Cognition Inc. (0001655923) (Filer)
- PRAlpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational UpdateZUNVEYL® net product revenue increased approximately 71% quarter-over-quarter to $6.0 million in the second quarter of 2026. Bottles dispensed increased approximately 37% quarter-over-quarter to 8,294, with monthly demand reaching 2,997 in June. Quarterly prescribers increased approximately 26% to 1,347 and repeat prescribers increased approximately 29% to 1,024, with approximately 76% prescribing in multiple months. Cash and cash equivalents totaled $41.4 million as of June 30, 2026, supporting the Company’s continued target of operating profitability in 2027 Company to host conference call and webcast today, August 13, at 4:30 p.m. ET. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha
- INSIDERLarge owner Opaleye Management Inc. bought $422,976 worth of shares (52,900 units at $8.00) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- PRAlpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business UpdateAlpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website. Following the release, management will host a conference call to review financial and operating results. Details for the conference call can be f
- PRAlpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s DiseaseAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additio
- INSIDERLarge owner Opaleye Management Inc. bought $1,027 worth of shares (130 units at $7.90) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. bought $1,565,499 worth of shares (200,086 units at $7.82) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
- ANALYSTRaymond James initiated coverage on Alpha Cognition with a new price targetRaymond James initiated coverage of Alpha Cognition with a rating of Outperform and set a new price target of $20.00
- PRAlpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision SummitAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET.For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to your institutional representative at B. Riley. There will be no live webcast of
ACOG FAQ
7 questionsWhat is the latest news on ACOG?
In the last 30 days Quantisnow tracked 5 wire items for ACOG: 2 press releases and news items, 2 insider trades and 1 earnings update. The most recent was published on November 2, 2026.What is ACOG revenue?
Alpha Cognition Inc. (ACOG) reported $15.26M of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $10.22M.Is ACOG profitable?
No. Alpha Cognition Inc. reported a net loss of $23.44M for the twelve months ended Jun 30, 2026.How much cash and debt does ACOG have?
Alpha Cognition Inc. reported $41.38M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ACOG stock trade?
Alpha Cognition Inc. (ACOG) is listed on NASDAQ.What are analysts saying about ACOG?
Alpha Cognition Inc. has had 5 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $21.00 price target on 2026-08-20. Recent price targets range from $12.00 to $21.00.How can I track ACOG on Quantisnow?
Quantisnow aggregates Alpha Cognition Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACOG to receive live email and push alerts on every new disclosure.